Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics

Takes up the non-executive role at the AI-focused medical imaging firm

Silence Therapeutics' chief executive officer Ali Mortazavi has been appointed non-executive chairman of ultromics - an artificial intelligence-focused medical imaging firm.

Mortazavi has 17 years’ experience in UK companies, particularly in the biotechnology investment field and joined London-based biotech Silence Therapeutics in 2012 leading its refinancing business and driving business.

He said: “I am truly excited to be joining the board of ultromics. Artificial intelligence will increasingly begin to play a bigger role in medicine as well as other sectors. Ultromics plans to use the combination of man plus machine rather than man vs Machine in medical imaging.”

Ultromics - formed in May 2017 - is backed by Oxford Sciences Innovation and the technology has been applied to echocardiograms to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%.

25th July 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics